QR Code

Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

Background: Relapsed/refractory acute lymphoblastic leukemia (ALL) remains a major clinical challenge. We have previously shown that relapsed leukemias frequently carry RAS-pathway activatingmutations that could be targeted by MEK-inhibitors in combination with glucocorticosteroids. Methods: Based o...

Full description

Saved in:
Main Authors: Britta Vormoor, Joshua Savage, Caroline Kristunas, Sarah Johnson, Mauricio Nicolás Ferrao Blanco, Geoff Shenton, Donna Lancaster, Anna Castleton, Adele K. Fielding, Anne-Louise Latif, Nick Morley, Marion Strullu, Ruta Tuckuviene, Pamela Kearns, Claire Jennings, Shelby Barnett, Gareth J. Veal, Julie Irving, Lucinda Billingham, Tobias Menne, Josef Vormoor
Format: Artigo
Language:Inglês
Published: Elsevier 2026-06-01
Series:EJC Paediatric Oncology
Subjects:
Relapsed/refractory acute lymphoblastic leukemia
Phase I/II clinical trial
MEK inhibitor
Selumetinib
Dexamethasone
RAS-pathway activating mutations
Online Access:http://www.sciencedirect.com/science/article/pii/S2772610X26000085
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items